Treatment-Resistant Depression in Colorado: Why More Denver Patients Are Trying Spravato

Treatment-Resistant Depression in Colorado: Why More Denver Patients Are Trying Spravato 

Treatment-resistant depression in Colorado is more common than most people think. Roughly one in three adults who start antidepressants don't fully respond, even after trying two or three medications at adequate dose and duration. Translated to the Denver metro alone, that's hundreds of thousands of people stuck in a cycle that traditional psychiatry isn't fully equipped to fix. Spravato is changing that — and it's why more of my patients each month are showing up after years of frustration. 

How common is treatment-resistant depression in Colorado? 

National data suggests around 30 percent of people with major depression don't reach remission on standard antidepressants. Colorado mirrors that pattern. With a Denver metro population of about 3 million and depression affecting roughly 8 percent of adults at any given time, the math gets uncomfortable: tens of thousands of Denver-area residents are walking around with depression that hasn't responded to what they've been offered. 

Why traditional medications stop working — or never start 

SSRIs and SNRIs are good medications. They work for a lot of people. But they target a single brain chemical (serotonin) and they take four to eight weeks to know if they'll help. If you have two failed trials at the right dose and duration, the odds of a third SSRI working drop significantly. That's not a personal failure. It's a mismatch between your specific brain chemistry and the available tools. 

What "treatment-resistant" actually means 

The clinical definition is straightforward: a diagnosis of major depressive disorder plus inadequate response to at least two different antidepressants at adequate dose and duration. That's it. There's nothing in that definition about how hard you've tried, how positive your attitude is, or whether you've "done the work." If you meet those two criteria, you have treatment-resistant depression — and you have options that go beyond another SSRI. 

How Spravato changes the picture 

Spravato (esketamine) works on glutamate and NMDA receptors — a different system from SSRIs. Onset is hours to days, not weeks. In clinical trials, roughly two-thirds of patients responded and about half reached remission. Equally important: it can be combined with the SSRI or SNRI you're already on, so it's an addition, not a switch. 

A composite Denver patient story 

One of our patients — I'll change the details — is a 47-year-old engineer in Highlands Ranch who'd been on six different antidepressants over fifteen years. Each one worked partially for a while, then stopped. She came in convinced this would be her seventh failure. By her fourth Spravato session, she was sleeping through the night for the first time in two years. By session eight, she had taken on a project at work she'd been avoiding for months. This pattern is not unusual. 

Three steps to take this week 

First, write down every antidepressant you've tried, the highest dose you took, and how long you stayed on it. Second, ask your prescriber whether you meet the clinical definition of treatment-resistant depression. Third, schedule a consultation with a Spravato-certified provider to find out if you qualify. You don't have to commit to anything to find out. 

Take our 5-minute eligibility check on our website to see if Spravato might be an option for you.